Skip to content
value.today
Bionano Genomics, Inc. logo

Bionano Genomics, Inc.

BNGO
$17 Mmarket cap on Oct 30, 2026-76.7% since Jan 2024
Compare
World rank
#24,827
Revenue
$29 M
For year ending December-2025
Net income
$-26 M
-92.6% margin
SEC filing
Employees
299
As on 2021
value.today research

Bionano Genomics, Inc. in brief

Bionano Genomics, Inc. is a listed company in the Diagnostics and Research industry, based in San Diego, California, USA. It was founded in 2003. Its market value was $17 M on 30 October 2026, which makes it the 24,827th largest listed company in the world and the 4,191st largest in the USA on this site. In the year to December 2025 it had sales of $29 M and a net loss of $26 M. It employs about 299 people and R. Erik Holmlin is its chief executive. Its largest product and service lines by sales in 2025 were Consumables (49%), Software (22%) and Instruments (22%). By market, the largest shares of its 2025 sales came from EMEA (49%), Americas (43%) and Asia Pacific (8%). Its shares trade under the symbol BNGO (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Bionano Genomics, Inc.

Bionano Genomics is a Developing Innovative Solutions company in the life sciences and health care industries. The company annual revenue is 8.5 million USD and 147 employees as on 2020. The headquarters is in USA.

Bionano Genomics, Inc. timeline

5 events, 2003–2023
  1. 2003
  2. 🏁
    · approximate
    Founded
  3. 2007
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2011
  6. ✎
    Renamed BioNano Genomics, Inc
    Formerly BioNanomatrix Inc.
  7. 2018
  8. 🔔
    Initial public offering on Nasdaq as BNGO
    Final prospectus filed with the SEC on 22 August 2018; shares registered for exchange trading on 17 August 2018.
  9. 2023
  10. 💰
    Record revenue of $36 million
    FY2023, the highest of the 8 years on record.

Events of Bionano Genomics, Inc. from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$212 M$425 M$637 M$850 M2020202120222023202420252026

World rank over time

▼ down 1,418 places since 2020
2020-01-01: #23426#23,42620202021-01-01: #11441#11,44120212022-01-07: #10719#10,71920222022-12-25: #13092#13,09220222023-07-30: #18627#18,62720232024-01-05: #23054#23,05420242026-03-08: #12679#12,67920262026-08-01: #22496#22,49620262026-10-08: #24292#24,29220262026-10-30: #24844#24,8442026

Rank in USA: #4,302 (Jan 2020) · #2,797 (Jan 2021) · #2,763 (Jan 2022) · #2,705 (Dec 2022) · #3,689 (Jul 2023) · #3,895 (Jan 2024) · #2,370 (Mar 2026) · #3,998 (Aug 2026) · #4,113 (Oct 2026) · #4,193 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
0.5×
Price / book
0.4×
Free cash flow yield
-228.2%
Net margin (TTM)
-96.8%
Operating margin
-116.9%
Return on equity
-67.8%
Liabilities / assets
39.6%
Net debt
$-25M
Revenue growth
-7.4%
R&D / revenue
39.9%
Revenue per employee
$95 K
Profit per employee
$-88 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $12M, net income $-19M$12MFY18Fiscal year ending Dec 2019: revenue $10M, net income $-30M$10MFY19Fiscal year ending Dec 2020: revenue $9M, net income $-41M$9MFY20Fiscal year ending Dec 2021: revenue $18M, net income $-72M$18MFY21Fiscal year ending Dec 2022: revenue $28M, net income $-133M$28MFY22Fiscal year ending Dec 2023: revenue $36M, net income $-232M$36MFY23Fiscal year ending Dec 2024: revenue $31M, net income $-112M$31MFY24Fiscal year ending Dec 2025: revenue $29M, net income $-26M$29MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$29M-7.4%$-33M$-26M-92.6%
Dec 2024$31M-14.8%$-104M$-112M-363.9%
Dec 2023$36M+29.9%$-215M$-232M-643.7%
Dec 2022$28M+54.6%$-132M$-133M-477.0%
Dec 2021$18M+111.5%$-77M$-72M-402.9%
Dec 2020$9M-16.1%$-39M$-41M-483.6%
Dec 2019$10M-15.6%$-26M$-30M-294.4%
Dec 2018$12M—$-20M$-19M-154.2%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-16M——$-4.85—
Dec 2024$-69M——$-88.13—
Dec 2023$-125M——$-408.60—
Dec 2022$-125M——$-4.58—
Dec 2021$-72M——$-0.26—
Dec 2020$-38M$0M$-38M$-0.39—
Dec 2019$-30M$0M$-30M$-1.99—
Dec 2018$-20M$0M$-20M$-2.61—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$31M
Net income, trailing 12 months
$-30M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $8M, net income $-20M$8MDec ’24Three months to Mar 2025: revenue $6M, net income $-3M$6MMar ’25Three months to Jun 2025: revenue $7M, net income $-7M$7MJun ’25Three months to Sep 2025: revenue $7M, net income $-9M$7MSep ’25Three months to Dec 2025 (from the annual report): revenue $8M, net income $-8M$8MDec ’25Three months to Mar 2026: revenue $7M, net income $-8M$7MMar ’26Three months to Jun 2026: revenue $8M, net income $-7M$8MJun ’26Three months to Sep 2026: revenue $8M, net income $-6M$8MSep ’26

Latest quarter to Sep 2026: revenue $8M (+12.3% on a year earlier), net income $-6M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Bionano Genomics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$29 M
Operating income
$-33 M
Net income
$-26 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$74 M
Total liabilities
$29 M
Total equity
$44 M

As of December-2025

Top 36 institutional investors in Bionano Genomics, Inc.#

As of Sep 30, 2026
36 institutions held 2.7 M shares (about 19.3% of the shares outstanding) on Sep 30, 2026. The ten largest hold 18.0%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Bionano Genomics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1AIGH Capital Management LLC1,165,000New8.33%$2 MNov 2, 2026
2Two Sigma Investments, LP483,557New3.46%$1 MNov 16, 2026
3Renaissance Technologies LLC154,000+102,900 (+201.37%)1.10%$0 MNov 12, 2026
4Vanguard Capital Management LLC138,786+56,398 (+68.45%)0.99%$0 MNov 13, 2026
5Carret Asset Management, LLC135,545+10,545 (+8.44%)0.97%$0 MNov 4, 2026
6HRT Financial LP96,866+85,126 (+725.09%)0.69%$0 MNov 13, 2026
7Gsa Capital Partners LLP92,384-57,900 (-38.53%)0.66%$0 MNov 16, 2026
8Acadian Asset Management LLC89,186New0.64%$0 MNov 9, 2026
9Jane Street Group, LLC86,321+50,593 (+141.61%)0.62%$0 MNov 12, 2026
10Geode Capital Management, LLC77,274-12,719 (-14.13%)0.55%$0 MNov 6, 2026
11Vanguard Fiduciary Trust Co51,5780 (0.00%)0.37%$0 MNov 13, 2026
12Prudential Financial Inc33,000+1,400 (+4.43%)0.24%$0 MNov 16, 2026
13Northern Trust Corp24,559-2 (-0.01%)0.18%$0 MNov 16, 2026
14UBS Group AG14,168+13,356 (+1644.83%)0.10%$0 MNov 10, 2026
15Engineers Gate Manager LP11,830-158 (-1.32%)0.08%$0 MNov 16, 2026
16Citadel Advisors LLC10,905New0.08%$0 MNov 16, 2026
17Warberg Asset Management LLC10,000New0.07%$0 MNov 2, 2026
18BlackRock, Inc.9,9370 (0.00%)0.07%$0 MNov 13, 2026
19Osaic Holdings, Inc.6,783-1,026 (-13.14%)0.05%$0 MNov 12, 2026
20Tower Research Capital LLC (TRC)2,989-2,239 (-42.83%)0.02%$0 MNov 16, 2026
21Bolton Securities Corporation1,0040 (0.00%)0.01%$0 MNov 12, 2026
22Group One Trading LLC9570 (0.00%)0.01%$0 MNov 10, 2026
23Morgan Stanley782-255 (-24.59%)0.01%$0 MNov 13, 2026
24National Bank Of Canada /fi/313+311 (+15550.00%)0.00%$0 MNov 16, 2026
25SBI Securities Co., Ltd.273+27 (+10.98%)0.00%$0 MOct 22, 2026
Show all 36: investors 26 to 36
Institutional investors 26 to 36 in Bionano Genomics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Wells Fargo & Company/mn1130 (0.00%)0.00%$0 MNov 16, 2026
27BNP Paribas Financial Markets130 (0.00%)0.00%$0 MNov 12, 2026
28Jpmorgan Chase & Co110 (0.00%)0.00%$0 MNov 12, 2026
29Royal Bank Of Canada110 (0.00%)0.00%$0 MNov 16, 2026
30Allworth Financial LP6New0.00%$0 MNov 17, 2026
31TD Waterhouse Canada Inc.50 (0.00%)0.00%$0 MOct 16, 2026
32Activest Wealth Management30 (0.00%)0.00%$0 MOct 15, 2026
33Barclays PLC2-1 (-33.33%)0.00%$0 MNov 6, 2026
34Atlantic Union Bankshares Corp10 (0.00%)0.00%$0 MNov 12, 2026
35Robinhood Markets, Inc.1—0.00%$0 MNov 18, 2026
36Medallion Wealth Advisors, LLC10 (0.00%)0.00%$0 MNov 13, 2026

Mutual funds holding Bionano Genomics, Inc.#

4 funds hold shares worth $0 M (about 1.5% of the company). Since their previous reports 2 added shares and 0 sold, buying $0 M net.
Mutual funds holding Bionano Genomics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC113,564$0 M0.81%<0.01%+119%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.82,388$0 M0.59%<0.01%+21%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC11,470$0 M0.08%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC2,769$0 M0.02%<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 4 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Bionano Genomics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$10 K
2 purchases, 1 insider
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$10 K
open market only
Insiders on file
20
since
$5 K$0Aug 2026: bought $5 K (1 trades), sold $0 (0 trades)Aug 26Sep 2026: bought $5 K (1 trades), sold $0 (0 trades)Sep
Bought (open market)Sold (open market)Hover a month for the totals
Bionano Genomics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Albert LudererInterim Chief Executive, DirectorBuyindirect+4,000$1.210$5 K8,000Form 4
filed Albert LudererInterim Chief Executive, DirectorBuyindirect+4,000$1.220$5 K4,000Form 4
filed Mark OldakowskiCHIEF OPERATING OFFICERShares withheld for tax-27$1.300$35868Form 4
filed Jonathan V. DixonGENERAL COUNSELShares withheld for tax-24$1.300$31239Form 4
filed Mark AdamchakPrincipal Accounting OfficerShares withheld for tax-7$1.300$9253Form 4
filed Alka ChaubeyCHIEF MEDICAL OFFICERShares withheld for tax-24$1.300$31620Form 4
filed Mark AdamchakPrincipal Accounting OfficerShares withheld for tax-3$1.100$3260Form 4
filed Jonathan V. DixonGENERAL COUNSELShares withheld for tax-6$1.100$7263Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Bionano Genomics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.4 M
12.9% of shares · 7.39 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-60.24 reverse split ; 1-for-10 reverse split ; 1-for-2 reverse split ; 1-for-21.41 reverse split

Trading halts

  • 2025-01-25 00:50 UTC, code T3, resumed 14:00 UTC

Fails to deliver

  • : 708 shares at $1.20
  • : 790 shares at $1.16
  • : 1,007 shares at $1.46
  • : 645 shares at $1.45
  • : 744 shares at $1.48

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Bionano Genomics, Inc. scorecard#

Passes 5 of the 19 checks that could be worked out: strongest in valuation (2 of 4), weakest in growth (1 of 6). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation2 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.4×Price to book 0.4× against Diagnostics and Research's median of 3.7×.
    • ✓Price to sales below its peers' median0.5×Price to sales 0.5× against Diagnostics and Research's median of 4.5×.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 6
    • ✗Revenue grew in the newest year-7.4%Revenue down 7.4% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years0.8%0.8% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median0.8%0.8% a year against Diagnostics and Research's median of 3.6% (64 companies).
    • ✗Earnings per share grew in the newest year-4.85 vs -88.13Diluted EPS -4.85 in fiscal 2025 against -88.13 the year before (report's currency).
    • ✓Net income higher than five years earlier-$26 M-$26 M in fiscal 2025 against -$41 M in 2020.
    • ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$26 MNet income -$26 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-116.9%-116.9% against Diagnostics and Research's median of -2.4% (66 companies).
    • ✗Return on equity above 15%-66.2%-66.2% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-116.9%-116.9% in fiscal 2025 against -473.7% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities2.0×Current ratio 1.98 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-14.09Z-score -14.09 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year328.4%Diluted shares up 328.4% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Bionano Genomics, Inc.'s statements, beside the median of Diagnostics and Research.

Bionano Genomics, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-116.9%-2.4%
Net margin-92.6%-3.6%
Return on equity-66.2%-5.4%
Revenue growth, 3 years a year0.8%3.6%
Revenue growth-7.4%6.6%

4of 8on the Piotroski tests of financial strength

  • Revenue fell 7.4% against the year before.
  • Net loss of $26 million, the 9th loss-making year in a row.
  • The share count rose 328.4% in the year.

Bionano Genomics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Bionano Genomics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017
Income statement
Revenue29313628188.5r10129.5
Cost of revenue15302722145.7r6.88.76.0
Research and development112554492210r9.19.512
Selling, general and administrative355293r895831r201414
Total costs and expenses471042251388141r292427
Operating income−33−104−215−132−77−39r−26−20−23
Interest and finance income1.01.53.31.50.4————
Interest expense and finance costs——5.10.30.92.5r2.31.40.6
Other non-operating income (expense)7.0−8.0−171.0−1.1−2.5r−3.91.9−0.1
Income before tax−26−112−232−131−78−41r−30−18−23
Income tax0.10.00.11.9−5.70.0r0.00.00.0
Net income including minority interests———−133−72−41r−30−18−23
Net income attributable to shareholders−26−112−232−133−72−41r−30−18−23
Earnings per share, basic-4.85-88.13-408.60r-4.58r-0.26-0.39-1.99-2.61-8.65
Earnings per share, diluted-4.85-88.13-408.60r-4.58r-0.26-0.39-1.99-2.61-8.65
Shares, weighted average (basic)5.41.30.6r29r277————
Shares, weighted average (diluted)5.41.30.6r29r277104r157.12.7
Balance sheet
Cash and cash equivalents3.09.2185.12538r17r171.0
Short-term investments160.3491082260———
Receivables5.24.89.37.04.92.8r6.3r4.53.4
Inventory7.8132830123.3r3.4r1.11.7
Other current assets1.81.3r1.0r2.4r1.4r0.5r0.5r0.40.6r
Current assets453914015727247r28r237.1
Property, plant and equipment15192318104.9r1.9r1.83.0
Right-of-use (leased) assets3.21.85.67.26.70———
Goodwill——077567.2r0——
Other intangible assets4.39.73441271.5r0——
Total assets747721430837760r30r2510
Accounts payable5.67.0101311r2.9r2.7r1.42.3
Debt due within a year—————020r06.7
Current liabilities233710036228.9r26r4.517
Long-term debt————016r09.00
Lease liabilities (non-current)2.50.13.65.55.30———
Total liabilities2941118584025r27r1517
Retained earnings−720−693−581−349−216−144r−103r−73−54
Shareholders' equity443596249r33735r3.6r10r−50
Total liabilities and equity747721430837760r30r2510
Shares outstanding111.90.8r30r290190r34r100.1
Cash-flow statement
Depreciation and amortization9.514149.63.41.5r1.11.31.5
Share-based compensation4.59.715229.71.6r1.31.20.4
Cash from operating activities−16−69−125−125−72−38r−30−20−21
Capital expenditure—————0−0.1−0.3−1.0
Intangible assets bought——0−0.10————
Acquisitions, net of cash acquired——0−31—−2.40——
Cash from investing activities−13742483−278−2.5r−0.1−0.3−1.0
Shares issued31445823—————
Cash from financing activities24−141142333662r303618
Exchange-rate effect on cash−0.0−0.00.1−0.00————
Change in cash−5.1−8.813−19−1421r0.816−4.2
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Bionano Genomics, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Product revenue(total)$27 M94%
  • Consumables$14 M49%
  • Software$6 M22%
  • Instruments$6 M22%
  • Service and other revenue$2 M6.2%

Business segments

  • Reportable$29 M100%

Countries and regions

  • EMEA$14 M49%
  • Americas$12 M43%
  • Asia Pacific$2 M7.8%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Bionano Genomics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.1 M
R. Erik Holmlin, Ph.D
Other top executives, average
$756 K
the CEO earned 1.5× this
$100 invested is now
$0
Bionano Genomics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025R. Erik Holmlin, Ph.D$1.1 M$1.0 M$756 K$0
2024R. Erik Holmlin, Ph.D$990 K$535 K$663 K$2
2023R. Erik Holmlin, Ph.D$1.5 M−$949 K$1.0 M$13

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Bionano Genomics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 3 · Material agreement 4 · Agreement ended 1 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 5 · Results announced 10

Bionano Genomics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Directors and officers8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Shareholder vote8-K/A
Directors and officersShareholder vote8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Agreement ended8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Shareholder vote8-K
Results announced8-K
Material agreement8-K
Material agreementUnregistered share sale8-K
Shareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

5 private funding rounds before listing

Private share sales · funding history

Private share sales of Bionano Genomics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2024$20 MPrivate placement after listing$10 to $50 million2optionsSEC
May 2024$20 MPrivate placement after listing$10 to $50 million4equity, debtSEC
Oct 2023$35 MPrivate placement after listing$10 to $50 million1debt, optionsSEC
Oct 2021$42 MPrivate placement after listing$10 to $50 million27equitySEC
Mar 2019$3 MPrivate placement after listing$2 to $10 million3equitySEC
Sep 2014$68 MNo. 5$50 to $250 million17equity, optionsSEC
Jun 2014$5 MNo. 4$2 to $10 million5debt, optionsSEC
Sep 2013$10 MNo. 3$10 to $50 million5debt, optionsSEC
Jun 2012$12 MNo. 2$10 to $50 million6equity, optionsSEC
Mar 2011$23 MNo. 1$10 to $50 million9equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Bionano Genomics, Inc.#

1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $95 K a year.

Certified, FY2025
1
#1,930 among companies on value.today
Worker positions
1
Median wage offered
$95 K
a year, full-time
Applications filed
1
Bionano Genomics, Inc.: most frequent H-1B job titles in fiscal 2025
Job titlePositionsMedian wage offered
Data AnalystBioinformatics Scientists1$95 K

Where: Boston, MA 1

Bionano Genomics, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202511$95 K1
FY202422$161 K2
FY202322$143 K2
FY202266$107 K6
FY202044$100 K4

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Bionano Genomics, Inc.

Layoffs at Bionano Genomics, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
214
2023–2024
Latest
84 people
2024-09-04
Bionano Genomics, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2024··64·····84···148
2023·········66··66
Bionano Genomics, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
84 people (45% of workforce)Restructuring planSEC 8-K“As part of the Reduction, the Company expects to reduce its overall headcount by approximately 84 employees, which represents approximately 45% of its full-time employees as of Sep…”Filing
Not statedRestructuring planSEC 8-KCompany-wide planFiling
effective 64 peopleLayoffWARN noticeSan Diego, CaliforniaNotice list
39% of workforceRestructuring planSEC 8-K“As part of the Reduction, the Company expects to reduce its overall headcount by approximately 110 to 125 employees, which represents approximately 34% to 39% of its full-time empl…”Filing
66 people (17% of workforce)Restructuring planSEC 8-K“As part of the Reduction, the Company expects to reduce its overall headcount by approximately 66 employees, which represents 17% of its full-time employees.”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Bionano Genomics, Inc. compares in Diagnostics and Research

  • Market cap$17 M · higher than 14% of 110
  • Revenue$29 M · higher than 21% of 123
  • Net margin-96.8% · higher than 11% of 112
  • Revenue growth-7.4% · higher than 19% of 89
  • Price / sales0.5× · lower than 94% of 85
  • Price / book0.4× · lower than 98% of 84

Peer comparison · Diagnostics and Research

CompanyMarket capP/ENet marginRev. growth
Bionano Genomics, Inc.🇺🇸$17 M—-96.8%-7.4%
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%
Danaher Corporation🇺🇸$166.7 B38.5×16.9%+2.9%
WuXi AppTec Co., Ltd.🇨🇳$70.4 B25.4×42.1%—
Natera, Inc.🇺🇸$58.7 B—-5.7%+35.9%
Siemens Healthineers AG🇩🇪$52.8 B22.9×8.7%—
Lonza Group AG🇨🇭$51.9 B—-4.2%—
Agilent Technologies, Inc.🇺🇸$48.8 B33.9×19.5%+6.7%
IQVIA Holdings Inc.🇺🇸$45.1 B32.4×8.1%+5.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on 2021
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, Wikidata, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Bionano Genomics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Bionano Genomics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Bionano Genomics, Inc.? Suggest a correction